InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.046

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Travelan application - Canada 4 Jun 2012 9:27AM $0.018 $0.046 risen by 155.56%
$15 Travelan Distribution in Singapore, Malaysia and Brunei 14 May 2012 9:41AM $0.018 $0.046 risen by 155.56%
$15 Travelan licensed to Thailand, Hong Kong, Cambodia, Vietnam 10 May 2012 9:45AM $0.018 $0.046 risen by 155.56%
$15 Agreement with Synlait Milk for Hyperimmune requirements 7 May 2012 9:44AM $0.017 $0.046 risen by 170.59%
$15 Reinstatement to Official Quotation 23 Apr 2012 10:19AM $0.020 $0.046 risen by 130%
$15 Capital Raising announcement 23 Apr 2012 10:19AM $0.020 $0.046 risen by 130%
$15 Suspension from Official Quotation 20 Apr 2012 9:35AM $0.026 $0.046 risen by 76.92%
$15 Trading Halt Request 18 Apr 2012 9:11AM $0.026 $0.046 risen by 76.92%
$15 Trading Halt 18 Apr 2012 9:07AM $0.026 $0.046 risen by 76.92%
$15 Immuron appoints Joe Baini Chief Executive Officer 5 Mar 2012 9:14AM $0.030 $0.046 risen by 53.33%
$15 Half Yearly Report and Accounts 28 Feb 2012 1:28PM $0.032 $0.046 risen by 43.75%
$15 Immuron and Monash University to Collaborate on C. difficile 31 Jan 2012 10:15AM $0.042 $0.046 risen by 9.52%
$15 Immuron finalises funding facility 16 Jan 2012 9:46AM $0.054 $0.046 fallen by 14.81%
$15 IND cleared for NASH/Fatty Liver Phase IIb trials 10 Jan 2012 9:07AM $0.050 $0.046 fallen by 8%
$15 Research agreement with Harvard Medical School 16 Dec 2011 9:26AM $0.040 $0.046 risen by 15%
$15 Travelan Licence Deal with Paladin Labs Inc. Canada 29 Nov 2011 9:17AM $0.050 $0.046 fallen by 8%
$15 Immuron submits NASH IND Application with FDA 7 Nov 2011 9:29AM $0.050 $0.046 fallen by 8%
$15 Non-Renounceable Issue Shortfall 4 Nov 2011 1:05PM $0.050 $0.046 fallen by 8%
$15 Offer Document for Non-Renounceable Rights Issue 31 Aug 2011 2:04PM $0.065 $0.046 fallen by 29.23%
$15 Results for Announcement to the Market 31 Aug 2011 12:55PM $0.050 $0.046 fallen by 8%
$15 Immuron`s Novel Influenza Product Advances to Human Trial 29 Aug 2011 9:01AM $0.066 $0.046 fallen by 30.30%
$15 Phase 2B NASH trial on track following meeting with FDA 22 Aug 2011 9:12AM $0.072 $0.046 fallen by 36.11%
$15 Notice of Non-Renounceable Rights Issue 17 Aug 2011 8:25AM $0.072 $0.046 fallen by 36.11%
$15 Travelan discovered to affect E.coli O104 outbreak in Europe 26 Jul 2011 10:29AM $0.072 $0.046 fallen by 36.11%
$15 HIV Program proceeds to Expanded Human Trial 21 Jul 2011 8:50AM $0.075 $0.046 fallen by 38.67%

726 - 750 of 782 results

Page 30 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.